Abstract: Provided herein are antibodies that bind signal regulatory protein gamma (SIRPy), as well as SIRP? and/or SIRP?1, and methods of using such antibodies (referred to as SIRP antibodies). In some embodiments, the SIRP antibodies are human monoclonal antibodies that bind human SIRPy as well as SIRP? and/or SIRP?1. In some embodiments, the SIRP antibodies provided herein are useful for treating a disease or condition associated with overactivation and/or hyperproliferation of lymphocytes, myeloid cells, or a combination thereof, or a disease or condition associated with SIRP?, SIRP?1 and/or SIRPy activity.

Abstract: Provided herein are antibodies that bind signal regulatory protein gamma (SIRP?), as well as SIRP? and/or SIR?1, and methods of using such antibodies (referred to as SIRP antibodies). In some embodiments, the SIRP antibodies are human monoclonal antibodies that bind human SIRP? as well as SIRP? and/or SIRP?1. In some embodiments, the SIRP antibodies provided herein are useful for treating a disease or condition associated with overactivation and/or hyperproliferation of lymphocytes, myeloid cells, or a combination thereof, or a disease or condition associated with SIRP?, SIRP?1 and/or SIRP? activity.

Abstract: Provided herein are antibodies that bind signal regulatory protein gamma (SIRP?), as well as SIRP? and/or SIRP?1, and methods of using such antibodies (referred to as SIRP antibodies). In some embodiments, the SIRP antibodies are human monoclonal antibodies that bind human SIRP? as well as SIRP? and/or SIRP?1. In some embodiments, the SIRP antibodies provided herein are useful for treating a disease or condition associated with overactivation and/or hyperproliferation of lymphocytes, myeloid cells, or a combination thereof, or a disease or condition associated with SIRP?, SIRP?1 and/or SIRP? activity.

Abstract: Provided herein are antibodies that bind signal regulatory protein SIRP? and methods of making and using such antibodies. In some embodiments, the antibodies comprise an Fc, and are useful for preferential depletion of certain SIRP? expressing cells. In some embodiments, the antibodies provided herein are useful for treating a disease or condition associated with the dysregulation of cells (e.g. overactivation or aberrant proliferation of T-cells).

Abstract: Provided herein are antibodies that bind signal regulatory protein gamma (SIRP?), as well as SIRP? and/or SIRP?1, and methods of using such antibodies (referred to as SIRP antibodies). In some embodiments, the SIRP antibodies are human monoclonal antibodies that bind human SIRP? as well as SIRP? and/or SIRP?1. In some embodiments, the SIRP antibodies provided herein are useful for treating a disease or condition associated with overactivation and/or hyperproliferation of lymphocytes, myeloid cells, or a combination thereof, or a disease or condition associated with SIRP?, SIRP?1 and/or SIRP? activity.

Abstract: Provided herein are antibodies that bind signal regulatory protein gamma (SIRPy), as well as SIRP? and/or SIRP?1, and methods of using such antibodies (referred to as SIRP antibodies). In some embodiments, the SIRP antibodies are human monoclonal antibodies that bind human SIRPy as well as SIRP? and/or SIRP?1. In some embodiments, the SIRP antibodies provided herein are useful for treating a disease or condition associated with overactivation and/or hyperproliferation of lymphocytes, myeloid cells, or a combination thereof, or a disease or condition associated with SIRP?, SIRP?1 and/or SIRPy activity.

Abstract: Provided herein are antibodies that bind signal regulatory protein SIRPa, SIRPß1, or a combination of SIRPa and SIRP?1, and methods of using such antibodies. In some embodiments, the antibodies are human monoclonal antibodies that bind human SIRPa and/or SIRP?1. In some embodiments, the antibodies provided herein are useful for treating a disease or condition associated with overactivation and/or hyperproliferation of myeloid cells, or a disease or condition associated with SIRPa and/or SIRP?1 activity.